News
KURA
13.38
-2.48%
-0.34
Bank of America Expects Small Caps to Beat Large Caps in 2023 — Here Are 2 Stocks That Wall Street Likes
TipRanks · 3d ago
Insider Sell: Kura Oncology
Insider Sell: Kura Oncology
MT Newswires · 3d ago
Stifel Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $25
Benzinga · 4d ago
Stifel Starts Kura Oncology at Buy With $25 Price Target
Stifel Starts Kura Oncology at Buy With $25 Price Target
MT Newswires · 4d ago
Kura Oncology: Good Cash, Some Good Data, A Few Problems
Seeking Alpha · 01/24 23:01
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/24 21:31
H.C. Wainwright Keeps Their Buy Rating on Kura Oncology (KURA)
TipRanks · 01/24 15:05
Brookline Capital Markets Sticks to Its Buy Rating for Kura Oncology (KURA)
TipRanks · 01/24 14:55
Why Kura Oncology Stock Is Moving Higher Tuesday Morning
Benzinga · 01/24 13:18
Kura Oncology wins FDA nod to start Phase 1 trial for solid tumor candidate
Seeking Alpha · 01/24 12:51
BRIEF-Kura Oncology Announces FDA Clearance Of Ind Application For Ko-2806, A Next-Generation Farnesyl Transferase Inhibitor
Reuters · 01/24 12:35
Kura Oncology Announced FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
Benzinga · 01/24 12:32
Kura Oncology Says FDA Clears Investigational New Drug Application for Advanced Solid Tumor Therapy
Kura Oncology Says FDA Clears Investigational New Drug Application for Advanced Solid Tumor Therapy
MT Newswires · 01/24 11:18
Kura Oncology (KURA) Receives a Buy from Jefferies
TipRanks · 01/18 13:15
SGMO, CDNS and HOLX are among after hour movers
Seeking Alpha · 01/13 22:58
Cramer Is Holding This Biotech Stock
Benzinga · 01/12 14:16
BRIEF-Kura Oncology Inc Announces Its Preliminary Unaudited Cash, Cash Equivalents And Short-Term Investments As Of Dec 31, 2022 Were About $438 Mln
Reuters · 01/09 12:49
Kura Oncology Granted U.S> Patent #11541045: Methods of treating cancer with farnesyltransferase inhibitors
Benzinga · 01/03 11:52
Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting
Benzinga · 12/12/2022 16:34
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
Benzinga · 12/12/2022 16:08
More
Webull provides a variety of real-time KURA stock news. You can receive the latest news about Kura Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company’s segment is engaged in discovery and development of medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. It is developing its product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and hematologic indications. It is developing KO-539, a small molecule inhibitor of the Lysine K-specific Methyltransferase 2A (KMT2A) interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The Company is developing orally available, small molecule compounds that inhibit the interaction between the proteins menin and MLL for the treatment of MLL-rearranged (MML-r) leukemias, a genetically-defined subset of approximately two forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic.